Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen.
Generation and characterization of B72.3 second generation monoclonal antibodies reactive with the tumor-associated glycoprotein 72 antigen.
复制标题
与肿瘤相关糖蛋白 72 抗原发生反应的 B72.3 第二代单克隆抗体的生成和表征。
作者：
R. Muraro;M. Kuroki;D. Wunderlich;D. Poole;D. Colcher;A. Thor;J. Greiner;J. Simpson;A. Molinolo;P. Noguchi;J. Schlom;R M Nih
单克隆抗体（MAb）B72.3使用人乳腺癌活检组织的膜富集部分产生。已证明其对大多数人腺癌（包括结直肠癌、胃癌、胰腺癌、卵巢癌、子宫内膜癌、乳腺癌和非小细胞肺癌）具有反应性，对正常成人组织（分泌期子宫内膜除外）无反应性或反应性较弱。B72.3反应性抗原，称为肿瘤相关糖蛋白（TAG）-72，已被纯化并用作免疫原以产生B72.3第二代单克隆抗体。由于纯化的TAG-72的来源是人结肠癌（CC）异种移植物，因此这些MAb被命名为CC。已经产生了28种CC MAb，均为免疫球蛋白G，并显示与TAG-72反应，并且通过放射免疫测定和免疫组织化学分析显示对癌与正常成人组织活检的不同反应性。选择九种CC MAb（CC 11、15、29、30、40、46、49、83和92）用于进一步表征。作为使用直接结合放射免疫测定法对一系列人类癌症、蛋白质印迹法、活细胞表面结合测定法、五种液体竞争放射免疫测定法和Ka测量法进行分析的结果，所有九种CC MAb可以彼此区分并与B72.3区分。B72.3的Ka测定为2.54 X 10（9）M-1;所有CC MAb均显示出较高的KaS，其中MAb CC 92、49和83的KaS分别为14.26、16.18和27.72 X 10（9）M-1。因此，这些研究表明，一种或多种抗TAG-72 CC MAb可能比B72.3更有效，或可与B72.3组合用于进一步研究人癌细胞群和目前利用MAb B72.3的诊断和治疗程序。
Monoclonal antibody (MAb) B72.3 was generated using a membrane-enriched fraction of a human mammary carcinoma biopsy. It has demonstrated reactivity to the majority of human adenocarcinomas including colorectal, gastric, pancreatic, ovarian, endometrial, mammary, and non-small cell lung cancer and no or weak reactivity to normal adult tissues, with the exception of secretory endometrium. The B72.3-reactive antigen, termed tumor-associated glycoprotein (TAG)-72, has been purified and used as an immunogen to generate B72.3 second generation MAbs. Since the source of purified TAG-72 was a human colon cancer (CC) xenograft, these MAbs have been given a CC designation. Twenty-eight CC MAbs, all immunoglobulin Gs, have been generated and shown to be reactive with TAG-72 and via both radioimmunoassay and immunohistochemical analyses show differential reactivity to carcinoma versus normal adult tissue biopsies. Nine CC MAbs (CC11, 15, 29, 30, 40, 46, 49, 83, and 92) were selected for further characterization. As a result of analyses using direct-binding radioimmunoassay to a range of human carcinomas, Western blotting, live cell surface binding assays, five liquid competition radioimmunoassays, and Ka measurements, all nine CC MAbs could be distinguished from each other and from B72.3. The Ka of B72.3 was determined to be 2.54 X 10(9) M-1; all the CC MAbs demonstrated higher KaS with MAbs CC92, 49, and 83 having KaS of 14.26, 16.18, and 27.72 X 10(9) M-1, respectively. These studies thus demonstrate that one or more of the anti-TAG-72 CC MAbs may be more efficient than B72.3, or useful in combination with B72.3, toward the further study of human carcinoma cell population and the diagnostic and therapeutic procedures presently utilizing MAb B72.3.
登录
查看更多内容
影响因子：
11.2
作者：
J. Magnani;Z. Steplewski;H. Koprowski;V. Ginsburg
通讯作者：
J. Magnani;Z. Steplewski;H. Koprowski;V. Ginsburg
影响因子：
11.2
作者：
A. Thor;N. Ohuchi;C. Szpak;W. Johnston;J. Schlom
通讯作者：
A. Thor;N. Ohuchi;C. Szpak;W. Johnston;J. Schlom
来自癌、良性肿瘤和正常组织的原代培养的人结肠上皮细胞中肿瘤相关抗原的表面表达。
影响因子：
11.2
作者：
Friedman,E;Thor,A;Hand,PH;Schlom,J
通讯作者：
Schlom,J
单克隆抗体（B72.3）定义的胸膜恶性间皮瘤和肺腺癌之间的诊断区别。
DOI：
--
发表时间：
1986
期刊：
The American journal of pathology
影响因子：
--
作者：
Szpak,CA;Johnston,WW;Roggli,V;Kolbeck,J;Lottich,SC;Vollmer,R;Thor,A;Schlom,J
通讯作者：
Schlom,J
使用单克隆抗体 (B72.3) 作为免疫细胞化学辅助手段诊断人类积液中的腺癌。
影响因子：
11.2
作者：
Johnston,WW;Szpak,CA;Lottich,SC;Thor,A;Schlom,J
通讯作者：
Schlom,J